Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MYGN Stock Forecast 2026-2027
$4.29
Current Price
$405.18M
Market Cap
Buy 2
Hold 6
Sell 2
Wall St Analyst Ratings
Distance to MYGN Price Targets
+319.6%
To High Target of $18.00
+39.9%
To Median Target of $6.00
-6.8%
To Low Target of $4.00
MYGN Price Momentum
-10.6%
1 Week Change
-3.4%
1 Month Change
+10.3%
1 Year Change
-30.2%
Year-to-Date Change
-50.1%
From 52W High of $8.59
+14.4%
From 52W Low of $3.75
📊 TOP ANALYST CALLS
Did MYGN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Myriad Genetics is one of their latest high-conviction picks.
Latest MYGN Stock Price Targets & Analyst Predictions
Based on our analysis of 23 Wall Street analysts, MYGN has a neutral consensus with a median price target of $6.00 (ranging from $4.00 to $18.00). The overall analyst rating is Buy (6.0/10). Currently trading at $4.29, the median forecast implies a 39.9% upside. This outlook is supported by 2 Buy, 6 Hold, and 2 Sell ratings.
The most optimistic forecast comes from Matthew Sykes at Goldman Sachs, projecting a 319.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MYGN Analyst Ratings
2
Buy
6
Hold
2
Sell
MYGN Price Target Range
Low
$4.00
Average
$6.00
High
$18.00
Current: $4.29
Latest MYGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MYGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 6, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| May 6, 2026 | TD Cowen | Hold | Maintains | $N/A | |
| Feb 24, 2026 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $6.00 |
| Feb 24, 2026 | UBS | Lu Li | Neutral | Maintains | $6.00 |
| Nov 11, 2025 | Piper Sandler | Dave Weiner | Overweight | Maintains | $8.50 |
| Nov 5, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $6.50 |
| Nov 4, 2025 | UBS | Lu Li | Neutral | Maintains | $8.00 |
| Nov 4, 2025 | TD Cowen | Dan Brennan | Hold | Maintains | $9.00 |
| May 21, 2025 | Scotiabank | Sung Ji Nam | Sector Perform | Downgrade | $6.00 |
| May 15, 2025 | Piper Sandler | Dave Weiner | Overweight | Maintains | $9.00 |
| May 8, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Downgrade | $6.00 |
| May 7, 2025 | UBS | Lu Li | Neutral | Maintains | $7.00 |
| May 7, 2025 | Raymond James | Andrew Cooper | Outperform | Reiterates | $10.00 |
| May 7, 2025 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $8.00 |
| Apr 17, 2025 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $14.00 |
| Apr 9, 2025 | Guggenheim | Subbu Nambi | Neutral | Downgrade | $N/A |
| Apr 1, 2025 | Scotiabank | Sung Ji Nam | Sector Outperform | Maintains | $20.00 |
| Mar 12, 2025 | Piper Sandler | Dave Weiner | Overweight | Upgrade | $12.50 |
| Mar 4, 2025 | Piper Sandler | Dave Weiner | Neutral | Maintains | $11.50 |
| Mar 3, 2025 | B of A Securities | Derik De Bruin | Underperform | Maintains | $11.00 |
Myriad Genetics Inc. (MYGN) Competitors
The following stocks are similar to Myriad Genetics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MYGN
Myriad Genetics
mkt cap
453.33M
Myriad Genetics Inc. (MYGN) Financial Data
Myriad Genetics Inc. has a market capitalization of $405.18M with a P/E ratio of -1.1x. The company generates $557.00M in trailing twelve-month revenue with a -41.3% profit margin.
Revenue growth is -20.8% quarter-over-quarter, while maintaining an operating margin of -21.4% and return on equity of -23.5%.
Valuation Metrics
Market Cap
$405.18M
Enterprise Value
$237.28M
P/E Ratio
-1.1x
PEG Ratio
0.0x
Price/Sales
0.7x
Growth & Margins
Revenue Growth (YoY)
-20.8%
Gross Margin
+68.7%
Operating Margin
-21.4%
Net Margin
-41.3%
EPS Growth
+2.3%
Financial Health
Cash/Price Ratio
+37.2%
Current Ratio
2.7x
Debt/Equity
32.8x
ROE
-23.5%
ROA
-7.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Myriad Genetics Inc. (MYGN) Business Model
About Myriad Genetics Inc.
What They Do
Develops genetic tests for cancer risk assessment.
Business Model
Myriad Genetics generates revenue by developing and commercializing a range of genetic tests that assess the risk of cancer and hereditary conditions. The company collaborates with healthcare providers, oncologists, and genetic counselors to deliver these tests, which support informed decision-making in disease prevention and treatment.
Additional Information
Headquartered in Salt Lake City, Utah, Myriad Genetics is a leader in molecular diagnostics, advancing personalized medicine through innovative genetic testing solutions. Their testing portfolio includes products that identify genetic markers for several cancers, significantly contributing to patient care and clinical decision-making.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
2,700
CEO
Mr. Samraat S. Raha
Country
United States
IPO Year
1995
Website
www.myriad.comMyriad Genetics Inc. (MYGN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of -56.52% and -1.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
May 06, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Myriad Genetics, Inc. (MYGN) held its Q1 2026 earnings call, providing updates on financial performance and company developments. Specific financial metrics and guidance were discussed.
Why It Matters
Myriad Genetics' Q1 2026 earnings may indicate financial health, growth potential, or challenges, impacting stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
In Q1 2026, revenue reached $200.4 million, up 2% YoY. Test volume grew in Cancer Care (13%) and Mental Health (7%), but Prenatal Health declined by 12%.
Why It Matters
The mixed revenue growth signals stability in key sectors but highlights challenges in Prenatal Health, which could impact overall profitability and future investment decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Myriad Genetics (MYGN) reported a quarterly loss of $0.09 per share, worse than the expected loss of $0.06, and a decline from a $0.03 loss per share a year earlier.
Why It Matters
Myriad Genetics' larger-than-expected quarterly loss signals potential operational challenges, raising concerns about its financial health and future growth prospects, impacting investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
The GeneSight® Mental Health Monitor by Myriad Genetics shows that many Americans believe mental health treatment does not cater to their individual needs.
Why It Matters
Consumer sentiment on mental health treatment can influence market demand for innovative solutions, impacting companies like Myriad Genetics and related sectors in healthcare.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Myriad Genetics, Inc. (NASDAQ: MYGN) will report its Q1 2026 earnings on May 5, 2026, with a conference call scheduled for 4:30 pm ET that day.
Why It Matters
Myriad Genetics' upcoming earnings report could impact stock prices, reflecting financial health and growth potential, influencing investor sentiment and decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for
11 days ago
Quick Summary
Myriad (MYGN) is not expected to meet the criteria for a potential earnings beat in its upcoming report, according to forecasts.
Why It Matters
Myriad's lack of favorable conditions for an earnings beat may lead to lower stock performance, impacting investor sentiment and share price.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About MYGN Stock
What is Myriad Genetics Inc.'s (MYGN) stock forecast for 2026?
Based on our analysis of 23 Wall Street analysts, Myriad Genetics Inc. (MYGN) has a median price target of $6.00. The highest price target is $18.00 and the lowest is $4.00.
Is MYGN stock a good investment in 2026?
According to current analyst ratings, MYGN has 2 Buy ratings, 6 Hold ratings, and 2 Sell ratings. The stock is currently trading at $4.29. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MYGN stock?
Wall Street analysts predict MYGN stock could reach $6.00 in the next 12 months. This represents a 39.9% increase from the current price of $4.29. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Myriad Genetics Inc.'s business model?
Myriad Genetics generates revenue by developing and commercializing a range of genetic tests that assess the risk of cancer and hereditary conditions. The company collaborates with healthcare providers, oncologists, and genetic counselors to deliver these tests, which support informed decision-making in disease prevention and treatment.
What is the highest forecasted price for MYGN Myriad Genetics Inc.?
The highest price target for MYGN is $18.00 from Matthew Sykes at Goldman Sachs, which represents a 319.6% increase from the current price of $4.29.
What is the lowest forecasted price for MYGN Myriad Genetics Inc.?
The lowest price target for MYGN is $4.00 from at , which represents a -6.8% decrease from the current price of $4.29.
What is the overall MYGN consensus from analysts for Myriad Genetics Inc.?
The overall analyst consensus for MYGN is neutral. Out of 23 Wall Street analysts, 2 rate it as Buy, 6 as Hold, and 2 as Sell, with a median price target of $6.00.
How accurate are MYGN stock price projections?
Stock price projections, including those for Myriad Genetics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 9, 2026 10:52 AM UTC